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Abstract 
Purpose of review: Since 2009 many broadly neutralizing antibodies against HIV 
have been identified yet there is still no vaccine capable of inducing such antibodies 
in humans. This review considers the early observations of HIV sera neutralization in 
light of more recent studies and highlights areas for future research. 
Recent findings: Large clinical cohort studies using standardized neutralization 
assays and pseudoviruses derived from primary isolates have shown that 10-30% of 
HIV infections result in some level of serum neutralization breadth. However, less 
than 10% of individuals develop a greater breadth of neutralization and are termed 
elite neutralizers. 
Summary: During HIV infection many individuals develop strain-specific 
neutralization against their viral quasispecies, and similar immunogen-matched 
activity can now be induced in animal models. However, only in a minority of 
infections do broadly neutralizing antibodies develop. Therefore, understanding how 
the viral diversity, host immune environment and antibody repertoires intersect to 
support the generation of neutralization breadth in elite neutralizers could provide 
guidelines as to how to improve immunization responses.  
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Introduction:  
The unusual degree of genetic variability of HIV-1, especially in the env gene that 
encodes the target for neutralizing antibodies, became apparent early on in the 
epidemic (1-5) and brought with it the concern that it would be difficult to develop an 
efficacious vaccine that could induce broadly neutralizing antibodies (bnAbs).  Early 
studies that examined the neutralization of HIV-1 by human sera from infected 
individuals set the agenda for the next 30 years of HIV vaccine research (6-14). 
These studies, allayed some fear; as although much neutralizing activity was strain-
specific at least some individuals developed neutralizing antibodies that were 
effective across diverse HIV-1 strains from around the globe (15, 16). Thus, despite 
the diversity in the HIV envelope protein (Env) there were conserved neutralizing 
epitopes. This review will provide an overview of the subsequent 30 years of 
research that resulted in a detailed picture of the development of neutralizing 
humoral responses during HIV infection. 
 
Early studies of HIV neutralization   
An obvious target for neutralizing antibodies was the viral interaction with the cell 
surface receptor CD4, which had already been identified as the major receptor for 
HIV entry into cells (17). Indeed the ‘group specific’ response was shown to include 
antibodies that inhibited CD4-envelope binding (18, 19).  The entry of HIV into its 
target cell is mediated by the highly glycosylated gp120 Env subunit, which is 
secured on the virion surface by the transmembrane gp41 Env subunit (20). 
Comparison of the gp120 sequences from various HIV isolates distinguished five 
variable regions (V1–V5) (4). The first four variable regions are exposed and held in 
loops by disulphide bonds (20). While the conserved regions of gp120 form a 
discontinuous structure, identified by mutagenesis to interact with CD4 (21-23). Thus, 
the CD4 binding site (CD4bs) was a likely candidate for conserved neutralizing 
epitopes. It was not understood at this time, but later became known, that when viral 
gp120 binds to CD4 it induces conformational changes that expose the V3 loop (24), 
which is the principal determinant of chemokine co-receptor interaction (CCR5 and 
CXCR4) (25-27). This CD4-induced exposure is indicated by the enhanced binding 
of several gp120-specific antibodies, in addition to those that recognize the V3 loop 
and CD4 binding site (28-31). These CD4-induced (CD4i) antibodies (32), similar to 
V3-loop antibodies, efficiently block the binding of gp120–CD4 complexes to the 
chemokine receptor (33-35).   
 
Despite the early optimism that broadly neutralizing targets could be identified a 
stumbling block quickly became apparent. Namely, that bnAb responses would be 
difficult to recapitulate in a vaccine using recombinant Env (6, 36). This was 
suggested because the first neutralizing antibodies to arise in human infection or in 
experimental infection of chimpanzees, targeted the V3 loop and only neutralized in a 
type-specific manner (37-39).  Furthermore, group-specific antibodies (now termed 
broadly neutralizing) developed only slowly, between one and two years after 
infection and not in all patients (15). These early studies were usually too small to 
make accurate estimates of how long it takes to develop bnAbs or in what fraction of 
infected patients they arose (40-42). Subsequent studies used viral isolates or Env 
clones derived directly from patients (autologous viruses) (43-45). The same picture 
emerged; variability among patients with respect to the time needed to develop 
autologous neutralization and a robust broadening of the response with time in only a 
minority of individuals. However, these early studies were plagued by cohort 
variability and a lack of consistency between neutralization assays employed 
including the use of viruses with varying degrees of neutralization sensitivity (46).  
Thus, the molecular details underpinning these responses would be required to 
generate a clear picture of the development of HIV neutralizing antibodies in vivo.   
 
How do bnAbs develop during infection? 
A key and consistent observation in studies of natural infection so far is that the 10-
30% of individuals whose serum is broadly neutralizing (Table 1), first make a strain-
specific response and then eventually shift to make a broader neutralizing response. 
Understanding how this shift to broad neutralization is achieved is key to vaccine 
development. How can it be mimicked to generate bnAb responses, both as an 
adjunct to therapy and in a classical protective vaccine? Detailed studies of bnAbs 
from mainly from the 1-10% of individuals with elite serum neutralization (as defined 
in each cohort – see Table 1) have begun to paint a picture that suggests that there 
are a number of ways to achieve bnAb activity. To date, five major bnAb sites have 
been identified: the CD4bs, the high mannose patch, the Env trimer apex, the gp120-
gp41 interface and the membrane proximal region (MPER), and these are 
extensively reviewed elsewhere (57, 58). It will be important know if this broad anti-
viral activity is achieved by multiple antibody lineages or by one or a few dominant 
expanded families. Studies on serum with bnAb-specific mutant viruses suggest that, 
at least in some cases, a limited number of epitopes are targeted within individuals 
(55, 59, 60). There are notable examples of expanded bnAb families within particular 
individuals that reconstiute their serum neutralization response (61-64). For example, 
one 15-year longitudinal study of the CD4bs-specific VRC01 bnAb family shows how 
the virus and antibody response mutate in a “cat and mouse” fashion during infection 
(65). In addition, structurally and genetically similar bnAbs to VRC01 have been 
identified in other HIV-infected people (66, 67) although it is important to note that 
neutralizing epitopes can be targeted by genetically unrelated bnAbs (68-70).  
How different HIV-specific antibody families impact one another during infection 
is relatively unknown. However, there is one intriguing example where a separate 
antibody family appears to help the development and expansion of a bnAb lineage 
within a particular individual (71).  Strikingly, the cooperating antibody lineage was 
later found to develop neutralization breadth independently (72). This provides 
support for the idea that the development of breadth is a stepwise process that will 
require sequential immunogens to guide the antibody response along the desired 
maturation pathway. This concept is also supported by a number of observations: 
Firstly, that early less-mutated bnAb family members have a limited degree of 
neutralization breadth (73); and secondly, some good news, that specifically 
designed immunogens (74) can re-elicit this level of breadth in Knockin mice which 
encode the bnAb precursor (75). Notably, the sequential immunogens used to elicit 
these bnAb-like antibodies were closely related allowing boosting of the preceding 
antibody response. However, in genetically outbred animal models, immunization 
largely only produces autologous neutralization of primary isolates. Recently, this has 
been found to be due in part to immunogenic autologous neutralizing epitopes 
accessible due to holes in the glycan shield of Env (76). This is reminiscent of the 
specificity of autologous neutralization often observed in natural infection (45).  
Therefore, the field has now produced antibodies by immunization that resemble the 
early neutralizing specificities induced during infection. Thus, the next step is to 
understand how neutralization breadth develops and mimic that by vaccination.  
Fundamental to this next step is to clearly define the involvement of strain-
specific antibodies in the development of breadth. One study has suggested breadth 
can arise to the same site as the early autologous neutralizing response, but with the 
broad antibody actually binding the N-linked glycan that enabled the virus to escape 
from the autologous neutralization (77). It seems unlikely this was due to direct 
affinity maturation of the autologous antibodies to recognise the N-linked glycan. 
More feasible is that viral escape resulted in heightened variation in this region 
(including the additional glycan site) that triggered the generation of de novo bnAb 
lineages. However, apart from this example (77), it has been observed that, some 
early bnAb family members can only neutralize in the absence of specific glycan 
sites proximal to their epitopes.  Such glycan shields are then tolerated by the related 
fully matured bnAbs (78, 79). In summary, the large body of work on bnAb lineages 
to date has provided clues as to how breadth develops, and the significance of the 
glycan shield in restricting neutralization breadth. Therefore, understanding what 
role, if any, strain-specific responses play in the step-wise development of 
neutralization breadth could suggest potential shortcuts to inducing breadth by 
immunization.  
Features associated with the development of bnAbs 
To recapitulate the shift from autologous to broad neutralization in vaccination it will 
also be valuable to understand why this occurs in some cases of natural infection 
and not others. To date, there are features associated with the development of 
neutralization breadth but no absolute predictive markers. The most consistent 
predictive trait of broad neutralization is a greater time of untreated infection, hence 
the preponderance of long-term non-progressors (LTNP) in broadly neutralizing 
cohorts (55, 56, 80, 81). Greater length of untreated infection occurs concurrently 
with greater viral diversity as quasi-species develop from the estimated 1-3 founder 
viruses (82). Furthermore, it has been suggested that greater diversity during the 
earliest stages of infection may have more influence on the development of breadth 
(83). However, in contrast to its association to the development of breadth, HIV Env 
sequence diversity poses a great barrier to the elicitation of bnAbs due to the 
extensive level of variation as reviewed in (84) and (85). In addition, Env adopts 
diverse conformational states, including non-infectious forms that can act as decoys 
for the immune response and by combining these multiple levels of variation HIV 
routinely escapes from host antibodies in ‘a mutational arms race’ (86, 87). 
Nevertheless, studies have suggested that viral subtype diversity can be overcome 
(88) and particular Env signatures are associated with the development of breadth 
(89). Moreover, intra-host Env diversity and viral escape from early neutralizing 
responses have been suggested to drive the maturation of broader responses (61, 
90). Thus, while Env diversity is a major roadblock to developing a protective 
antibody response following immunization paradoxically it is also a probable trigger 
of bnAb development. 
 
Another key aspect of the development of broad HIV neutralization is the host 
immune system. The role of particular bnAb genetic precursor prevalence may play a 
role but has not been directly assessed in large cohort studies and is expertly 
reviewed elsewhere (91). There have been limited reports on the role of immune cell 
subsets, primarily that low CD4 counts correlate with breadth (49, 52, 55), but this 
could potentially be related to high viral load. In addition, neutralization breadth has 
been associated with higher levels of T follicular helper (TFH) cells expressing PD1 
in human subjects (92).   TFH cells have also been found to be important in the 
development of broad antibody responses in non-human primate infections (93). 
Recent data from a very large human cohort show a trend to greater likelihood of 
bnAb-like serum responses in individuals of African ethnicity (56). Furthermore, a 
separate genome-wide association study in the Amsterdam Cohort found single-
nucleotide polymorphism in MHC and HLA-B to be most strongly associated with 
breadth but not significant at a genome level (94). These observations suggest the 
overall host immune enivronment plays a role in the generation of bnAbs, as do 
studies showing that more rapid development of neutralization breadth can occur (<1 
year). Particularly as this can occur in immunlogically distinct situations, such as 
transmission following injecting drug use (95) or from mother-to-child (96). Therefore, 
there is a need to further elucidate the role of host biology in the development of 
bnAb responses. 
 
The bnAb revolution  
Over the last decade the identification of bnAbs has revolutionized our understanding 
of the humoral response to HIV (57, 97). The rapid isolation of so many bnAbs was 
possible due to advances in screening assays to identify individuals with broadly 
neutralizing serum as reviewed in (58). Critically, this involved the generation of large 
panels of Env pseudoviruses derived from primary isolates and categorization of their 
neutralization sensitivity, to exclude easily neutralized strains (98-100). These tools 
enabled neutralization breadth to be investigated in large cohort studies as 
summarized in Table 1 (47, 48, 50, 52-55). A clearer picture emerged; breadth of 
neutralization develops in 10-30% of individuals generally 2-3 years after infection, 
despite the use of different definitions of breadth, virus panels and clinical 
populations between studies. Notably, elite neutralization, where breadth is 
equivalent to that seen with individual bnAbs, is less frequent, arising in 1-10% of 
individuals (Table 1). These large cohort studies are largely consistent with early 
observations of the rapid rise of autologous neutralization activity followed by the 
later, and less frequent, development of breadth (43, 44). Additionally, longitudinal 
serum studies have also shown the early development of autologous neutralization 
and resulting selection of viral escape mutations within individuals (45, 101, 102). 
These strain-specific responses have been seen as early as two weeks post 
seroconversion and escape seen in response to low titers of autologous neutralizing 
antibodies (103). However, despite the fact that viral Env mutation within the host is 
largely driven by the need to escape the autologous neutralizing response, there is 
no apparent consequent loss of viral fitness (104) which raises the question of how 
effective humoral responses are after transmission during chronic infection? 
 
Early studies that attempted to correlate neutralizing antibodies with 
protection were disappointing. There was no decline in viremia with the development 
of either autologous or broad neutralization (43, 44, 105, 106). Indeed, one study 
suggested that patients could harbor viruses sensitive to neutralization despite the 
presence of serum antibodies that potently neutralize these particular strains (107). 
Nor is there evidence that development of neutralization breadth improves patient 
prognosis (51, 108) . The observation that broad neutralization is predominantly 
found in LTNP compared to rapid progressors (47, 49, 51, 53) may be attributable to 
sustained exposure to the viral Env antigen over long periods.  In contrast rapid 
progressors become virally suppressed on treatment, which limits antigenic 
stimulation Despite these shortcomings the evolution of neutralization escape 
mutants in vivo was often clearly observed (44, 45, 109). Furthermore, contemporary 
circulating HIV strains are more resistant to bnAbs compared to historical strains 
(110, 111). This suggests that overall there is evolutionary pressure on HIV to 
escape the onslaught of neutralization activity within individuals that controls 
diversification of the virus to some degree. In agreement with this, it is known that 
bnAbs can protect from infection in animal models, reviewed in (112), and recently 
human bnAb therapy has increased time to viral re-bound (113).  Furthermore, pre-
existing anti-HIV antibodies have been reported to prevent the emergence of escape 
mutants to the administered bnAb (114) further supporting the idea of using bnAbs to 
treat chronic infection.  	
Conclusion 
Many lessons have been learnt from studying the humoral response to HIV both 
in terms of serological studies and characterization of bnAbs and their family 
members. First, antibodies can be effective against HIV from the observation that the 
presence of early neutralizing antibodies drives the evolution of the viral Env within 
the host. Second, HIV bnAbs possess a level of neutralization breadth and potency 
previously thought impossible, renewing hope that a protective vaccine can be 
developed. Third, although virus can overcome neutralizing antibodies if it is 
established in the host before antibodies develop, as in natural infection, but not if 
antibodies are present in advance, as in passive transfer studies. Fourth, 
development of breadth is a question of balance; not only is diversity important but 
so too is time.  High enough viral diversity over at least a year of infection is generally 
needed to stimulate a bnAb response but excessive viral replication, resulting in 
rapid progression and immune dysregulation, will not favour breadth. Finally, 
absolute predictors of neutralization breadth have not been identified. This suggests 
additional factors should be investigated such as the balance of different antibody 
specificities and lymphocyte subsets, along with genetic host factors. However, the 
interplay of host and viral factors that result in broad neutralization will likely vary 
between individuals, as HIV bnAbs are a diverse group which can arise from multiple 
pathways of antigenic stimulation. In summary, despite great advances in our 
understanding of humoral responses to HIV, what controls the tipping point that leads 
to broad neutralization remains to be defined. 
Key points:  
• Despite early optimism neutralizing responses are difficult to recapitulate in a 
vaccine 
• Clinical cohort studies show that broad neutralization occurs in 10-30% of HIV 
infections 
• Elite HIV serum neutralization is seen in <10% of individuals 
• More research is needed to understand the shift from strain-specific to broad 
HIV neutralization during infection and how it varies between different people. 
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Figure legends: 
Table 1: Selected serological studies assessing breadth of neutralization 
response in HIV infection. 
Summary data from the indicated cohort studies which have attempted to measure 
breadth and potency of HIV neutralization in serum samples. Abbreviations: IAVI = 
International AIDS Vaccine Iniative, NIH = National Institutes of Health. 
Cohort 
Viruses 
screened 
No. 
patients Author defined breadth Time frame 
IAVI Protocol G (47) 
Multiple panels: N =1798 
 
Single time point: 3 years onwards 
101 virus panel n = 101 Broad = 45% had an IC50 titer of ≥150 for viruses from 1-3 clades 
15 of above 
viruses 
n = 463 
Broad = 36% had IC50 titers of ≥150 for viruses from >4 clades 
Intermediate = 51% had an IC50 titer of ≥100 for viruse from 1-3 clades 
6 representative 
viruses 
n = 1234 
Broad = 34% had IC50 titer of ≥100 against >4 clades, Elite breadth = 1% had mean IC50 
titer of 1:500 to majority viruse from >4 clades. 
NIH (48) 5 virus panel n = 113 
Broad = 33% neutralized 4/5 viruses, Intermediate = 33% 3/5 viruses,  
no breadth = 29% 0 or 1/5 viruses 
Single time point: 1 year onwards 
Amsterdam Cohort (49) 28 virus panel n = 35 
Broad = IC50 >100 for >50% of viruses per subtype, from >3 subtypes, 20% broad at 2 
years, 31% broad at 4 years 
Longitudinal: breadth observed 2 
and 4 years after seroconversion 
South African National Blood 
Services (50) 
10 virus panel n = 70 Broad = 23% neutralized all 10 viruses Single time point: 180 days onwards 
Amsterdam Cohort  
(51) 
23 virus panel n = 82 Broad = 33%, moderate = 48% and no breasth = 20% 
Single time point: ~35 months after 
seroconversion 
Caprisa Cohort  
(52) 
44 virus panel n= 40 Broad = 17.5% neutralized > 40% of viruses 
Longitudinal: peak titer at 3 years 
after seroconversion 
Ragon Institute  
(53) 
20 virus panel n = 17 Broad = 29% neutralized 75% viruses 
Longitudinal: breadth observed at 1-
2.5 years 
Multiple (54) 219 virus panel n = 205 Broad = 50% neutralized >50% of viruses, Elite breadth = 10% neutralized 90% of viruses 
Single time point: chronic HIV 
infection 
IAVI Protocol C  
(55) 
6 virus panel n = 439 
Broad = 2% elite >2, 9% strong (1-2), 25% moderate (0.5-1) and not broad = 46% low (0.1-
0.5), 18% no breadth 
Longitudinal: 0-4 years 
Swiss Cohort (56) 8 virus panel n = 4484 
Cummulative scoring for % neutralization. Elite (score >15) = 1.3%, Broad (score 10-14) = 
4%, cross-neutralizing (score 5-9) = 15.6% 
Single time point: >1 year off 
treatment 	
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